Copyright
©The Author(s) 2021.
World J Clin Cases. Nov 16, 2021; 9(32): 9869-9877
Published online Nov 16, 2021. doi: 10.12998/wjcc.v9.i32.9869
Published online Nov 16, 2021. doi: 10.12998/wjcc.v9.i32.9869
Group | n | Time | CD3+ (%) | CD4+ (%) | CD4+/CD8 (%) | CD8+ (%) |
Experimental | 35 | Before treatment | 41.52 ± 5.21 | 32.07 ± 3.31 | 0.51 ± 0.15 | 52.25 ± 5.37 |
After treatment | 62.3 ± 5.53a,d | 43.4 ± 4.99a,d | 1.02 ± 0.29a,d | 40.52 ± 4.58a,d | ||
Control | 33 | Before treatment | 42.52 ± 4.58 | 31.15 ± 3.25 | 0.55 ± 0.13 | 52.12 ± 6.59 |
After treatment | 53.25 ± .6.62a | 37.72 ± 4.56a | 0.77 ± 0.15a | 48.46 ± 5.58a |
- Citation: Li Z, Yin DF, Wang W, Zhang XW, Zhou LJ, Yang J. Efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in patients with colorectal cancer after operation. World J Clin Cases 2021; 9(32): 9869-9877
- URL: https://www.wjgnet.com/2307-8960/full/v9/i32/9869.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i32.9869